1. 1409PAssociation of efficacy and immune-related adverse events (irAEs) in patients with NSCLC receiving immune-checkpoint inhibitors (ICIs). (23rd October 2018) Authors: Riudavets Melia, M; Gabriela Sullivan, I; Barba Joaquín, A; Anguera Palacios, G; del Carpio, L P; Molto Valiente, C; Camacho Arellano, S D; Moron Asensio, S; Gomila Pons, P; Andres Granyó, M; Castillo Villegas, D; Facundo Molas, C; Garcia Planella, E; González Blanco, C; Barnadas Molins, A; Gich ... Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1468PGECP 1605/NIVEX TRIAL nivolumab in the real world: The SPANISH expanded access program experience in pretreated advanced NSCLC. (23rd October 2018) Authors: Majem Tarruella, M; Campillo, J; Grau Béjar, J F; Carcereny, E; Bernabe Caro, R; Garcia, Y; Artal-Cortes, A; González Cao, M; Lianes, P; Paredes Lario, A; Sereno Moyano, M; Mielgo Rubio, X; Macias, J A; Provencio Pulla, M; Rodriguez-Abreu, D Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗